MSN Labs inks deal with Lilly to launch baricitinib By IANS | Published on Thu, May 13 2021 14:48 IST | 18 Views MSN Labs inks deal with Lilly to launch baricitinib. Image Source: IANS News Hyderabad, May 13 : MSN Labs (MSN) on Thursday announced it has entered into a royalty free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for Covid-19 in India. The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).